



## *Biotech Life Sciences - A 20/20 Vision to 2020*

This document provides details of the contents and discussion in Biotech 2008 Life Sciences: A 20/20 Vision for 2020, the 22nd annual report on the biotechnology industry from Burrill & Company.

The publication examines the yearly performance of the biotech industry, makes predictions for the upcoming year, and provides insight how scientific, business and policy developments today will alter the healthcare landscape in 2020. One of the important accelerating trends reshaping the biotechnology industry is the emergence of personalized medicine.

For more information please click on:

[http://www.researchandmarkets.com/product/c441b9/biotech\\_life\\_sciences\\_a2020\\_vision\\_to\\_2020](http://www.researchandmarkets.com/product/c441b9/biotech_life_sciences_a2020_vision_to_2020)

Laura Wood  
Senior Manager  
Research and Markets Ltd  
laura.wood@researchandmarkets.com

### Biotech 2008 Key Findings:

- The convergence of genomics, information technology, and nanotechnologies will radically alter every aspect of the healthcare system from the way companies develop and market drugs to the way individuals pay for and receive medical services
- The biotech industry finished 2007 in good shape with a strong performance on the capital markets, which remained unpredictable all year long
- The year saw 28 new biotech IPOs; financings and partnering deals collectively raising almost \$45 billion for US companies. Although the industry had no difficulty raising money it had a tough time bringing new medicines to market with the prevailing safety-conscious attitude at the FDA taking its toll on new drug approvals

- Demand for bio-ethanol, bio-diesel, and other alternative energy sources is driving technological innovation in the sector, especially in the production of cellulosic ethanol. Biotech crop acreage grew 12 percent and 12 million farmers around the world are benefiting from biotechnology.
- Internationally, biotechnology showed steady growth with China and India leading the way.

Predictions for 2020:

- Wal-Mart, plus other direct to consumer healthcare delivery institutions, will become the place to go for medical treatment.
- Your Blackberry will constantly monitor your health and alert your doctor of any problems.
- Nano-devices in the blood will diagnose and repair problems.
- Patients will carry their genome and health records on a smartcard.
- To be successful, companies will have to retool from being full-integrated to a virtually-integrated model
- People will be able to purchase organs off-the-shelf or even grow their own.
- Our ability to design and test new drugs using computer simulations ("in silico"), as well as new capabilities to test for harmful side effects on model systems assembled on computer chips ("lab-on-a-chip") will continue to improve
- Implants and prostheses that mimic biological functions, restore critical functions to existing organs or tissues, or even augment those functions will begin to appear.

For more information please click on:

[http://www.researchandmarkets.com/product/c441b9/biotech\\_life\\_sciences\\_a2020\\_vision\\_to\\_2020](http://www.researchandmarkets.com/product/c441b9/biotech_life_sciences_a2020_vision_to_2020)

Title Index:

Chapter 1: 20/20 Vision to 2020:

Our Vision

Healthcare

AgBio

The Global Scene

Business Models and Market Cap

Chapter 2: Industry Metrics:

2007 Snapshot

The Capital Markets  
Financings  
M&A/Partnering  
Regulatory  
Biofuels in the Melting Pot  
Global Biotech Crop Area Increased  
International  
Burrill's Predictions for Biotech in 2008

Chapter 3: Healthcare:  
Pharma Readies for the Future  
Modest Growth Predicted for Pharmaceutical Market  
Mixed Year for Pharma and Biotech  
Pharma's Top-Selling Drugs Starting to Peak  
Steady Growth for Biotech Drugs  
Product Approvals  
Selected Major Setbacks in 2007  
Innovation Gap Still Wide  
Healthcare Spending  
Personalized Medicine  
Investors Wowed by Personalized Medicine  
Diagnostics Companies Have a Good Year  
Companion Diagnostics  
Reimbursement is Critical  
Dx Attracts Venture Capital and Suitors

Chapter 4: Wellness:  
Consumers Want a Quality Experience  
Big Food Goes Healthy  
Wall Street Performance  
M&A  
Investors Whet Their Appetite  
The International Market  
The Regulatory Arena  
Wellness and Prevention: The New Watchwords of Healthcare  
Nutrigenomics Advances Personalized Nutrition  
Healthy Aging  
Using Beauty Drugs and Foods to Slow the Advance of Time  
Organic Becomes Mainstream  
Targeting Obesity  
Biotech and Pharma Weigh In  
Functional Foods for Weight Control  
Edible Remedies  
Medical Foods and Plant-based Therapies  
Functional Foods  
Probiotics: Focus on Digestive Health

Supplements  
Looking Ahead

Chapter 5: Emerging Technologies:  
Technologies Impacting Healthcare  
Systems Biology  
From Sequences to Systems Biology  
Systems Biology Alters Drug Development  
Nanomedicine  
Nanotubes  
Nanowires  
Nanodiagnostics  
NIH Roadmap 2008  
Human Microbiome Project  
Epigenomics  
The Quest for the \$1,000 Genome  
The X PRIZE  
Human Whole-Genome Sequencing  
Illumina Sequences Genome of African Male  
Scientists Create First Synthetic Bacterial Genome  
The Power of RNA  
RNA Interference-Switching Genes Off  
RNA Activation-Switching Genes On  
MicroRNA-Great Potential in Diagnostics and Treatments  
Gene Therapy  
Genomics: Back on the Radar Screen

Chapter 6: Politics and Policy:  
FDA Amendments Act: Higher Fees, Enhanced Safety  
PDUFA IV: Booming User Fees  
Trials Registry and Databank  
Conflict of Interest Waivers  
What We Talk About When We Talk About Preemption  
Post-Vioxx: The Need for Improved Drug Safety  
FDAAA and Safety  
Medical Device User Fee and Modernization Act  
Changing Landscape  
Diagnostics and Devices  
Genomics: The Future of Safety?  
The Genomics and Personalized Medicine Act of 2007  
Personalized Medicine Milestone: Warfarin  
IVDMIA: FDA Revises Draft Guidance  
MammaPrint: The First  
Report Roundup: Genetics Tests and Nanotech Draw Scrutiny from Federal  
Agencies  
Other Device and Diagnostic News

Patents: Worrisome Patent Changes on the Horizon  
In the Courts  
New USPTO Rules  
Patent Reform Legislation  
Storm Warnings  
Global Stem Cell Developments  
Asia Moves Forward With Stem Cell Research  
Other Stem Cell News  
Asian Trends  
An Overview of EU Developments

Chapter 7: Agbio:  
The Gene Revolution Transforms the Green Revolution  
Companies Drive Innovation  
Monsanto: A Long List of Deals  
Syngenta Goes East-To China and Australia  
Dow Goes South-To Latin America  
DuPont: Busy Globally  
Brazil: A Growing Player  
Transgenics Become Mainstream  
Global Metrics  
Countries Move to Develop Own GM Technology  
US Farmers Embrace Transgenics  
Genetic Modification Taking Root in Europe-Slowly  
The Changing Regulatory Landscape  
Enabling Technologies  
RNA Interference as a Pesticide  
Bioremediation  
Enhancing the Nutritional Quality of Food  
Molecular Breeding, a Next-Generation Technology  
Plant-Made Pharmaceuticals Become a Reality  
Transgenic Animals  
Looking Ahead

Chapter 8: Industrial Biotech and Biofuels:  
The New Bio-Economy  
International Initiatives  
The United States: the Energy Independence and Security Act of 2007  
Corporate Developments  
Companies Push into the Global Market  
Oil Companies Get Green  
Cleantech Fuels VC Interest  
Alternative Energy Gets US Government Backing  
Bioenergy  
Ethanol  
Cellulosic Ethanol/Biomass

Biodiesel  
Algae: A Potential Next-Generation Feedstock  
Using Synthetic Biology to Make Designer Microbes  
Microbial Fuel Cells  
Bioplastics  
Integrated Biorefineries  
Biochememicals  
Looking Ahead

Chapter 9: International:

Europe  
Denmark  
Canada  
Australia/New Zealand  
China  
Japan  
Malaysia  
India

Chapter 10: M&A/Partnering:

Activity Down  
Select M&A Transactions  
\$5-Billion-plus Deals  
\$1-Billion-plus Deals  
Specialty Sector Transactions  
Cancer  
Trends  
Regional M&A  
Partnering  
Deal Activity  
The Top  
Regional Alliances  
Analysis of Transactions  
The Outlook to 2020

Chapter 11: Finance & Capital Markets:

No Shortage of Capital for Biotechs  
Positive Year for Biotech IPOs  
China Connection  
Other IPO Winners  
On the Runway  
PIPEs-an Essential Vehicle for Biotech  
Follow-Ons  
Debt  
Venture Capital at Record Levels  
Positive Performance on Capital Markets

Billion-Dollar Club  
Burrill Mid-Cap Index  
Burrill Small-Cap Index  
Creative Financing and Listing Alternatives  
Euronext  
Biotech Platform  
Looking Ahead  
Industry Financial Data Reconciliation  
Companies Ranked by December 31, 2007 Market Cap  
Companies in Alphabetical Order

Chapter 12: About Burrill & Company:  
Burrill & Company  
Venture Capital  
International  
Greater China Group  
India Group  
Japan Group  
Latin America Group  
Malaysia Group  
Middle East Group  
Advisory Boards  
Large Corporate Limited Partners  
Portfolio Companies  
Private Equity  
Merchant Banking  
Media

#### Pricing

Electronic (PDF) (Single User) : EUR 190  
Hard Copy : EUR 276

#### Ordering - Three easy ways to place your order:

1] Order online at

[http://www.researchandmarkets.com/product/c441b9/biotech\\_life\\_sciences\\_a2020\\_vision\\_to\\_2020](http://www.researchandmarkets.com/product/c441b9/biotech_life_sciences_a2020_vision_to_2020)

2] Order by fax: Print an Order form from

[http://www.researchandmarkets.com/product/c441b9/biotech\\_life\\_sciences\\_a2020\\_vision\\_to\\_2020](http://www.researchandmarkets.com/product/c441b9/biotech_life_sciences_a2020_vision_to_2020) and Fax to +353 1 4100 980

3] Order by mail: Print an Order form from

[http://www.researchandmarkets.com/product/c441b9/biotech\\_life\\_sciences\\_a2020\\_vision\\_to\\_2020](http://www.researchandmarkets.com/product/c441b9/biotech_life_sciences_a2020_vision_to_2020) and post to Research and Markets Ltd. Guinness Center, Taylors Lane, Dublin 8. Ireland

Subscribe: Click on <http://www.researchandmarkets.com/register.asp> You can subscribe free for regular details on new research in your sector.